Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ASLAN Pharmaceuticals Limited - American Depositary Shares (NQ:ASLN)

0.6000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ASLAN Pharmaceuticals Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 Next >
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
Via Benzinga
Dow Jumps 200 Points; Synchrony Financial Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%
ASLAN Pharmaceuticals shares are trading lower by 40.6% during Wednesday's session. The company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary... 
Via Benzinga
Crude Oil Rises 2%; Five Below Shares Plunge
Via Benzinga
Nasdaq Dips 300 Points; Johnson & Johnson Earnings Top Estimates
Via Benzinga
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Crude Oil Moves Lower; Goldman Sachs Posts Upbeat Results
Via Benzinga
Why SolarEdge Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet
Via Benzinga
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Falls In July
Via Benzinga
Topics Stocks
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024
ASLN stock results show that ASLAN Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023
ASLN stock results show that ASLAN Pharma missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.